Skip to main content
SpringerLink
Log in
Book cover

Angiotensin II AT1-Rezeptorantagonisten pp 39–75Cite as

Pharmakologie und klinische Pharmakologie der AT1-Rezeptorantagonisten

  • Conference paper

  • 24 Accesses

Zusammenfassung

Seit 1980 standen mit den ACE-Hemmern (damals Captopril) erstmals Substanzen für die antihypertensive Therapie in Deutschland zur Verfügung, die ihre Angriffspunkte am Renin-Angiotensin-Aldosteron-System (RAAS) hatten und nicht, wie die bis zu diesem Zeitpunkt verfügbaren Antihypertensiva, die auf das sympathische System (zentral oder peripher), an der Niere oder auf die glatte Muskulatur wirkten. Auch ß-Adrenozeptoranta- gonisten beeinflussen das RAAS, indem sie die ß1-Adrenozeptoren am juxtaglomerulären Apparat der Niere blockieren und so zu einer verminderten Bildung und Freisetzung des Schlüsselenzyms für die Angiotensin (Ang)-II-Biosynthese, des Renins, beitragen, aber dies ist nicht ihre Hauptwirkung.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anderson GH, Jr, Streeten DHP, Dalakas TG (1977) Pressor responses to l-Sar-8-Ala-Ang II (saralasin) in hypertensive subjects. Circ Res 40: 243–250

    CAS  PubMed  Google Scholar 

  2. Bader M, Zhao Y, Sander M, Lee MA, Bachmann MA, Bachmann S, Böhm M, Dyavidani B, Peters J, Mullins J, Ganten D (1992) The transgenic rats TGR(mREN2) 27: role of tissue renin in the pathophysiology of hypertension. Hypertension 19: 681–686

    CAS  PubMed  Google Scholar 

  3. Bauer PH, Chiù AT, Garrison JC (1991) Effects of nonpeptide Ang II receptor antagonists on Ang II stimulated second messenger production in rat liver. FASEB J 5 (Part I): A870

    Google Scholar 

  4. Böhm M, Lee MA, Kreutz R et al. (1995) Angiotensin II receptor blockade in TGR(mREN2) 27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens 13: 891–9

    PubMed  Google Scholar 

  5. Boucher R, Asselin JH, Genest J (1974) A new enzyme leading to direct formation of angiotensin II. Circ Res 34 (Suppl 1): 1203–1209

    Google Scholar 

  6. Bovee KC, Wong PC, Timmermanns PBMWM, Thoolen MJMC (1991) Effects of nonpeptide Ang II receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs. Am J Hypertens 4 (Part 2): 327S-333S

    CAS  PubMed  Google Scholar 

  7. Bovy PR, Olins GM (1992) Recent advances in nonpeptidic Ang II receptor antagonists. Current Drugs: Renin Angiotensin System. Current Patents Ltd., Middlesex House, London, pp B17-B34

    Google Scholar 

  8. Brasch H, Sieroslawski L, Dominiak P (1993) Ang II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension 22: 699–704

    CAS  PubMed  Google Scholar 

  9. Brilla CG, Zhou G, Weber KT (1992) Ang II and collagen synthesis in cultured adult rat cardiac fibroblasts. J Hypertens 10 (Suppl 4): S125

    Google Scholar 

  10. Brooks DP DePalma PD, Ruffolo RR Jr (1992b) Effect of Captopril and the nonpeptide angiotensin II antagonists. SK&F 108566 and EXP3174, on renal funcdon in dogs with a renal artery stenosis. J Pharmacol Exp Ther 263: 422–7

    CAS  PubMed  Google Scholar 

  11. Brooks DP, Frederickson TA, Kissinger JT et al. (1993) Blood pressure lowering activity of enalapril and the nonpeptide angiotensin II receptor antagonist, SK&F 108566, in furosemide-treated conscious cynomol- gus monkeys. Pharmacol Commun 2 (4): 331–7

    CAS  Google Scholar 

  12. Brooks DP, Fredrickson TA, Weinstock J et al. (1992a) Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs. Naunyn Schmiedebergs Arch Pharmacol 345: 673–8

    CAS  Google Scholar 

  13. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, Weber B, Brunner HR (1995) Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 25: 602–609

    CAS  PubMed  Google Scholar 

  14. Burnier M, Rutschmann B, Nussberger J et al. (1993) Salt-dependent renal effects of an Ang II antagonist in healthy subjects. Hypertension 22: 339–347

    CAS  PubMed  Google Scholar 

  15. Busch U, Heinzel G, Roth W (1997) Animal pharmacokinetics of telmisartan and their applicadon to man [poster]. 1st Internadonal Symposium on Angiotensin II Antagonism; Sept. 28-Oct 1; London

    Google Scholar 

  16. Camargo MJF, Von Lutterotti N, Pecker MS et al. (1991) DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet. Am J Hypertens 4/4, Part 2: 341S-345S

    Google Scholar 

  17. Cangiano JL, Rodriguez-Sargent C, Martinez-Maldonado M (1979) Effects of antihypertensive treatment on systolic blood pressure and renin in experimental hypertension in rat. J Pharmacol Exp Ther 208: 310–313

    CAS  PubMed  Google Scholar 

  18. Captopril multicenter Research group (1983) A placebo-controlled trial of Captopril in refractionary chronic congestive heart failure. J Amer Coll Cardiol 2: 755–763

    Google Scholar 

  19. Case DB, Wallace JM, Larach JH (1979) Comparison between saralasin and converting enzyme inhibitor in hypertensive disease. Kidney Int 15: S107-S114

    Google Scholar 

  20. Cazaubon C, Gougat J, Guiraudou P, Broussier D, Lacour C, Rocon A, Galindo G, Barthélémy G, Gautret B, Nisato D (1992) In vitro and in vivo pharmacology of SR47436, an Ang II receptor antagonist. Am J Hypertens 5 (Part 2): 19A-20A

    Google Scholar 

  21. Chansel D, Czekalski S, Pham P et al. (1992) Characterization of Ang II receptor subtypes in human glomeruli and mesangial cells. Am J Physiol 262 (3): F432-F441

    CAS  PubMed  Google Scholar 

  22. Chiù AT, McCall DE, Nguyen TT, Carini DJ, Duncia JV, Herblin WF, Wong PC, Wexler RR, Johnson AL, Timmermans PBMWM (1989) Discriminadon of Ang II receptor subtypes by dithiothreitol. Eur J Pharmacol 170:117–118

    PubMed  Google Scholar 

  23. Chiù AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PBMWM (1990) Nonpeptide Ang II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP753, on orally acdve antihypertensive agent. J Pharmacol Exp Ther 252: 711–718

    PubMed  Google Scholar 

  24. Christ DD (1995) Human plasma protein binding of the Ang II receptor antagonist losartan potassium (DuP753/MK 954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol 35: 515–520

    CAS  PubMed  Google Scholar 

  25. Christen Y, Waeber B, Nussberger J, Lee RJ, Timmermans PBMWM, Brunner HR (1991) Dose-response relationships following oral administration of DuP753 to normal humans. Am J Hypertens 4 (Part 2): 350S-353S

    CAS  PubMed  Google Scholar 

  26. Christen Y, Waeber B, Nussberger J, Porchet M, Lee R, Maggon K, Shum L, Timmermans PBMWM, Brunner HR, Borland RM (1991) Oral administradon of DuP753, a specific angiotensin II antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation 83: 1333–1342

    CAS  PubMed  Google Scholar 

  27. Chua CC, Chua BHL, Diglio CA, Siu BB (1992) Inducdon of endothelin-1 transcript by Ang II in rat heart endothelial cells. FASEB J 6: A1636

    Google Scholar 

  28. Cogan MG, Xie MH, Liu FY et al. (1991) Effects of DuP753 on proximal nephron and renal transport. Am JHypertens 4 (4):315S-320S

    CAS  Google Scholar 

  29. Crawford KW, Frey EA, Cote TE (1992) Ang II receptor recognized by DuP753 regulates two distinct guanine nucleotide-binding protein signaling pathways. Mol Pharmacol 41: 154–162

    CAS  PubMed  Google Scholar 

  30. Criscione L, Bradley WA, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, de Gasparo M (1995) Valsartan, Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 13: 230–250

    CAS  Google Scholar 

  31. Criscione L, de Gasparo M, Buehlmayer P, Whitebread S, Ramjoue HP, Wood JM (1993) Pharmacological profile of valsartan: A potent, orally active, nonpepdde antagonist of the Ang II AT,-receptor subtype. Br J Pharmacol 110:761–771

    CAS  PubMed Central  PubMed  Google Scholar 

  32. Data on file, Bristol Myers Squibb/Sanofi

    Google Scholar 

  33. Data on file, Ciba

    Google Scholar 

  34. Data on file, Merck Sharp & Dohme

    Google Scholar 

  35. Data on file, SmithKline Beecham

    Google Scholar 

  36. De Gasparo M, Whitebread S (1995) Binding of valsartan to mammalian AT, receptors. Regul Pept 59: 303–311

    PubMed  Google Scholar 

  37. DeLeon H, Bonhomme MC, Thibault G et al. (1993) Reassessment of ANF and ANG II receptors in rat mesenteric arteries. Abstr, Hypertension 22 (3): 424

    Google Scholar 

  38. de Zeeuw D, Remuzzi G, Kirch W (1997) Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 11 (Suppl 2): S37–42

    PubMed  Google Scholar 

  39. Delacrétaz E, Nussberger J, Biollaz J et al. (1995) Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 14–21

    Google Scholar 

  40. Dendorfer A, Raasch W, Tempel K, Dominiak P (1998) Interactions between the renin-angiotensin system (RAS) and the sympathetic system. Basic Res Cardiol 93: Suppl 2, 24–29

    CAS  PubMed  Google Scholar 

  41. Dendorfer A, Simon M, Dominiak P (1996) Herzwirksame Hormone: Bradykinin. Z Kardiol 85 (Suppl 6): 211–218

    CAS  PubMed  Google Scholar 

  42. Deutsche Liga zur Bekämpfung des hohen Blutdruckes e.V., Deutsche Hypertonie Gesellschaft, Heidelberg: Empfehlungen zur Hochdruckbehandlung in der Praxis und zur Behandlung hypertensiver Notfälle. 12. Auflage, Stand November 1996

    Google Scholar 

  43. Dickstein K, Timmermans P, Segal R et al. (1998) Losartan: a selective angiotensin II Type 1 (AT,) receptor antagonist for treatment of heart failure. Exp Opin Invest Drugs 7: 1897–1914

    CAS  Google Scholar 

  44. Dominiak P, Blöchl A (1991) Does converting enzyme inhibition change the neuronal and extraneuronal uptake of catecholamines? Basic Res Cardiol 86 (Suppl 3): 149–156

    PubMed  Google Scholar 

  45. Dominiak P, Bonner G (1996) ACE-Hemmer in Klinik und Praxis. Aktuelle Therapieprinzipien in Kardiologie und Angiologie. Springer, Berlin, Heidelberg

    Google Scholar 

  46. Dominiak P, Brenner P, Simon M, Blöchl A (1994) Angiotensin I increases adrenaline release and Ang II noradrenaline overflow in control and kininogen deficient Brown-Norway rats. Pharm Pharmacol Lett 4: 23–26

    CAS  Google Scholar 

  47. Dominiak P (1993) Modulation of sympathetic control by ACE inhibitors. Eur Heart J 14 (Suppl I): 169–172

    CAS  PubMed  Google Scholar 

  48. Dominiak P (1955) Stand und Probleme der ACE-Hemmer-Behandlung. Was ist gesichert in der Therapie? ZAllg Med 71: 587–594

    Google Scholar 

  49. Drexler H, Lindpaintner K, Lu W, Schieffer B, Ganten D (1989) Transient increase in the expression of cardiac angiotensinogen in a rat model of myocardial infarction and failure. Circulation 80:11–450

    Google Scholar 

  50. Dzau VJ, Gonzalez D, Kaempfer C, Dubin D, Wintroub BU(1987) Human neutrophils release serine proteases capable of activating prorenin. Circ Res 60: 595–601

    Google Scholar 

  51. Dzau VJ, Sasamura H, Hein L (1993) Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 11 (Suppl 3): S13-S18

    Google Scholar 

  52. Edwards RM, Aiyar N, Ohlstein EH, Weidley EE, Griffin E, Ezekiel M, Keenan RM, Ruffolo RR Jr, Weinstock J (1992) Pharmacological characterization of the nonpeptide Ang II receptor antagonist, SK&F108566. J Pharmacol Exp Ther 260: 175–181

    CAS  PubMed  Google Scholar 

  53. Fauvel JP, Laville M, Maakel N et al. (1994) Effects of losartan on renal hemodynamic parameters in hypertensives (abstract). J Hypertens (Suppl 3) 12: S93

    Google Scholar 

  54. Fornes P, Richer C, Vacher E et al. (1993) Losartan‘s protective effects in stroke prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 22: 305–313

    CAS  PubMed  Google Scholar 

  55. Fridman K, Wysocki M, Friberg P et al. (1998) Long-term effects of candesartan cilexetil on the systemic and renal haemodynamics in moderately hypertensive patients [abstract]. Am J Hypertens 11 (4 Pt2): 77A

    Google Scholar 

  56. Furakawa Y, Kishimoto S, Nishikawa K (1982) Hypotensive imidazole derivatives and hypotensive imidazole-5-acetic acid derivatives. Patents issued to Takeda Chemical Industries Ltd. on July 20,1982, and October 19, 1982, respectively, U.S. Patents 4,340,598 and 4,355,040, Osaka, Japan

    Google Scholar 

  57. Ganten D, Mulrow PJ (eds) (1990) Pharmacology of Antihypertensive Therapeutics. Handbook of Experimental Pharmacology, Vol 93. Springer, Berlin Heidelberg

    Google Scholar 

  58. Gillis JC, Markham A (1997) Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 54: 885–902

    Google Scholar 

  59. Goa KL, Wagstaff AJ (1996) Losartan Potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 51: 820–845

    CAS  PubMed  Google Scholar 

  60. Hagino T, Abe K, Tsunoda K, Yoshinaga K (1992) Chronic effects of MK-954, a nonpeptide Ang II receptor antagonist, on 24-hour ambulatory blood pressure, renin angiotensin aldosterone system and renal function in essential hypertension. J Hypertens 10 (Suppl 4): 224

    Google Scholar 

  61. Hansson L, Lindholm LH, Niskanen L, Lauke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire V, Morlin C, Karlberg BE, Wester PO, Bjorck JE (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 20, 353: 611–616

    Google Scholar 

  62. Harding JW, Wright JW, Swanson GN, Hanesworth JM, Krebs LT (1994) AT4 receptors: specificity and distribution. Kidney Int 46: 1510–1512

    CAS  PubMed  Google Scholar 

  63. Häuser W, Dendorfer A, Nguyen T, Dominiak P (1998) Effects of the AT 1 Antagonist HR 720 in Comparison to Losartan on Stimulated Sympathetic Outflow, Blood Pressure, and Heart Rate in Pithed Spontaneously Hypertensive Rats. Kidney Blodd Press Res 21: 29–35

    Google Scholar 

  64. Hübner R, Högemann AM, Sunzel M et al. (1997) Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 11 (Suppl 2): 19–25

    Google Scholar 

  65. Ilson BE, Martin DE, Boike SC, Jorkasky DK (1998) The effects of eprosartan, an angiotensin II ATI receptor antagonist, on uric acid excredon in patients with mild to moderate essential hypertension. J Clin Pharmacol 38: 437–41

    CAS  PubMed  Google Scholar 

  66. Inagami T, Murakami T, Higuchi K, Nakajo S (1991) Roles of renal and vascular renin in spontaneous hypertension and switching of mechanism upon nephrectomy: lack of hypotensive effects of inhibidon of renin, converting enzyme, Ang II receptor blocker after bilateral nephrectomy. Am J Hypertens 4: 15S-22S

    CAS  PubMed  Google Scholar 

  67. Inoue Y, Nakamura N, Inagami T (1997) A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor acdvadon mechanism. J Hypertens 15: 703–714

    CAS  PubMed  Google Scholar 

  68. Kagoshima T, Masuda J, Sutani E et al. (1994) Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats. Blood Press 3 (Suppl 5): 89–93

    Google Scholar 

  69. Kanagy NL, Fink GD (1992) Losartan (DuP 753) prevents salt-induced hypertension in reduced renal mass rats. FASEB 16: A1810

    Google Scholar 

  70. Kebabian JW, Neumeyer JL (eds) (1994) The RBI Handbook of Receptor Classificadon. Research Bio- chemicals International, pp 10–11

    Google Scholar 

  71. Kessler-Icekson G, Schlesinger H, Cohen F (1992) Effect of Ang II and losartan on protein accumulation in cultured heart myocytes and nonmyocytes. FASEB J 6: A1872

    Google Scholar 

  72. Khairallah PhA (1972) Action of angiotensin on adrenergic nerve endings: inhibition of norepinephrine uptake. Fed Proc 31: 1351–1357

    CAS  PubMed  Google Scholar 

  73. Kirby RF, Nanda A, Henry M, Johnson AK (1992) Preweanling losartan treatment reduces adult blood pressure in the spontaneously hypertensive rat. FASEB J 6: A1872

    Google Scholar 

  74. Kojima M, Shiojima I, Yamazaki T et al. (1994) Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circuladon 89: 2204 -11

    CAS  Google Scholar 

  75. Lewis EJ, Hunsicker LG, Bain RP, Rohde RO (for the Collaboradve Study Group) (1993) The effect of angiotensin-converdng-enzyme inhibidon on diabetic nephropathy. New Engl J Med 329: 1456–1462

    CAS  PubMed  Google Scholar 

  76. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA (1995) Contribudon of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47: 25–49

    CAS  PubMed  Google Scholar 

  77. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA (1997) Effects of angiotensin- converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99: 1926–35

    CAS  PubMed Central  PubMed  Google Scholar 

  78. Lo MW, Goldberg MR, McCrea JB et al. (1995) Pharmacokinetics of losartan, an Ang II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58: 641–649

    CAS  PubMed  Google Scholar 

  79. Majewski H, Hedler L, Schurr C, Starke K (1984) Moduladon of noradrenaline release in the pithed rabbit: a role for Ang II. J Cardiovasc Pharmacol 6: 888–896

    CAS  PubMed  Google Scholar 

  80. Markham A, Goa KL (1997) Valsartan. A Review of its Pharmacology and Therapeutic Use in Essendal Hypertension. Drug 54 (2): 299–311

    CAS  Google Scholar 

  81. Martin DE, Tompson D, Boike SC, Tenero D, Ilson B, Citerone D, Jorkasky DK (1997) Lack of effect of eprosartan on the single dose pharmacokinedcs of orally administered digoxin in healthy male volunteers. Br J Clin Pharmacol 43: 661–4

    Google Scholar 

  82. Martineau D, Yamaguchi N, Briand R (1995) Inhibidon by BMS 186295, a selecdve nonpepdde ATI antagonist, of adrenal catecholamine release induced by angiotensin II in the dog in vivo. Can J Physiol Pharmacol 73: 459–64

    CAS  PubMed  Google Scholar 

  83. Mardnez F, Schmitt F, Savoiu C, Leenhardt AF, Brouard R, Peronnet P, Lacour B, Grünfeld JP (1994) Effect of SR 47436 (BMS-186295) on renal hemodynamics and on glomerular permselectivity in healthy humans. JAm Soc Nephrol 5: 607

    Google Scholar 

  84. Matsubara K, Brilla CG, Weber KT (1992) Ang Il-mediated inhibidon of collagenase activity in cultured cardiac fibroblasts. FASEB J 6: A941

    Google Scholar 

  85. McClellan KJ, Balfour JA (1998) Eprosartan. Drugs 55: 713–720

    CAS  Google Scholar 

  86. McClellan KJ, Goa KL (1998) Candesartan Cilexedl. A review of its Use in Essendal Hypertension. Drugs 56:847–869

    CAS  PubMed  Google Scholar 

  87. McClellan KJ, Markham A (1998) Telmisartan. Drugs 56: 1039–1046

    CAS  PubMed  Google Scholar 

  88. Mclnnes GT, O’Kane KPJ, Jonger J et al. (1997) The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 11 (Suppl 2): S75–80

    Google Scholar 

  89. Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T (1996) The Ang II AT, receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol 122: 59–67

    CAS  PubMed  Google Scholar 

  90. Meinecke I, Feltkamp H, Högemann A et al. (1997) Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - a population analysis. Eur J Clin Pharmacol 53: 221–8

    Google Scholar 

  91. Miwa K, Murakami H, Masaki K et al. (1997) In vitro metabolism of candesartan cilexetil [abstract]. In: 1st International Symposium on Angiotensin II Antagonism Sep 28-Oct 1; London, 1997

    Google Scholar 

  92. Mizuno K, Niimura S, Katoh K et al. (1994) TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats. Life Sci 54 (25): 1987–94

    CAS  PubMed  Google Scholar 

  93. Morsing P, Brandt-Eliasson U, Abrahamsson T (1998) Candesartan, an insurmountable antagonist of angiotensin II mediated contractile effects in isolated vascular preparations: a comparison with irbesartan, losartan and its active metaboHte (EXP3174) [abstract]. Am J Hypertens 11 (4 Pt2): 37A

    Google Scholar 

  94. Morton JJ, Beattie EC, McPherson F (1991) Ang II receptor antagonist DuP753 reduces long-term post- treatment hypertension in the young spontaneously hypertensive rat: relation to vascular hypertrophy. Biophys J 59 (Part 2): 99A

    Google Scholar 

  95. Müller P, Cohen T, deGasparo M, Sioufi A, Racinepoon A, Howald H (1994) Ang II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 47: 231–245

    PubMed  Google Scholar 

  96. Müller-Esterl W (1993) The realm of the kinins. Biomedical Progress 6: 49–53

    Google Scholar 

  97. Murphy DD, Shepard J, Smith SG III, Stephens GA (1992) Effects of the AT, receptor antagonist losartan on Ang II induced hypertrophy of rat cardiomyocytes. FASEB J 6: A1261

    Google Scholar 

  98. Nagano M, Higaki J, Mikami H et al. (1994) Role of renin-angiotensin system in hypertension in the elderly. Blood Press 3 (Suppl 5): 130–3

    Google Scholar 

  99. Nakashima M, Uematsu T, Kosuge K (1992) Pilot study of the uricosuric effect of DuP-753, a new Ang II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42: 333–335

    CAS  PubMed  Google Scholar 

  100. Neutel JM, Smith DHG (1998) Dose Response and Antihypertensive Efficacy of the AT, Receptor Antagonist Telmisartan in Patients with Mild to Moderate Hypertension. Advances in Therapy 15: 206–217

    CAS  Google Scholar 

  101. Nguyen T, Häuser W, Dominiak P (1995) Blockade von AT, -Rezeptoren mit S 4509 A reduziert die prä- und postsynaptische Antwort auf Ang II an spontan hypertensiven Ratten. Z Kardiol 84 (Suppl 1): 221–771

    Google Scholar 

  102. Nisato D, Cazaubon C, Lacour C, Gougat J, Guiraudou P, Bemhart C, Perreaut P, Breliere JC, LeFur G (1992) Pharmacological properties of SR 47436, a non-peptidic Ang II receptor antagonist. Br J Pharmacol 105: 84P

    Google Scholar 

  103. Nishikawa K, Inada Y, Shibouta Y et al. (1994) Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist. TCV-116. Blood Press 3 (Suppl 5): 7–14

    Google Scholar 

  104. Nishikawa K, Naka T, Chatani F, Yoshimura Y (1997) Candesartan cilexitil: a review of its preclinical pharmacology. J Hum Hypertension 11 (Suppl 2): S1-S7

    Google Scholar 

  105. Nishikimi T, Yamagishi H, Takeuchi K (1995) An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res 29: 856–61

    CAS  PubMed  Google Scholar 

  106. Nöda M, Fukuda R, Matsuo T et al. (1997) Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. Kidney Int 52 (Suppl 63): SI36–139

    Google Scholar 

  107. Nöda M, Shibouta Y, Inada Y et al. (1993) Inhibition of rabbit aortic angiotensin II (All) receptor by CV-11974, a new nonpeptide All antagonist. Biochem Pharmacol 46: 311–8

    PubMed  Google Scholar 

  108. Ohlstein EH, Brooks DP, Feuerstein GZ et al. (1997) Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 55: 244–51

    CAS  PubMed  Google Scholar 

  109. Ohtawa M, Takayama F, Saitoh K (1993) Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide Ang II receptor antagonist, in humans. Br J Clin Pharmacol 35: 290–297

    CAS  PubMed Central  PubMed  Google Scholar 

  110. Ojima M, Inada Y, Shibouta Y et al. (1997) Candesartan (CV-11974) dissociates slowly from the angiotensin AT, receptor. Eur J Pharmacol 319: 137–46

    CAS  PubMed  Google Scholar 

  111. Okada M, Kobayashi M, Satoh N et al. (1993) Effect of chronic treatment with losartan on development of hypertension in stroke prone spontaneously hypertensive rats (SHRSP): Comparative study with enalapril and hydralazine. Hypertens Res 16: 49–55

    CAS  Google Scholar 

  112. Okunishi H, Miyazaki M, Toda N (1984) Evidence for a putatively new Ang Il-generating enzyme in the vascular wall. J Hypertens 2: 277–284

    CAS  PubMed  Google Scholar 

  113. Pals DT, Mascucci FD, Denning GS, Sipos F, Fessler DC (1971) Role of the pressor action of Ang II in experimental hypertension. Circ Res 29: 673–681

    CAS  PubMed  Google Scholar 

  114. Peach MJ, Bumpus FM, Khairallah PhA (1971) Release of adrenal catecholamines by angiotensin I. J Pharmacol Exp Ther 176: 366–376

    CAS  PubMed  Google Scholar 

  115. Peach MJ (1971) Adrenal medullary stimulaüon induced by angiotensin I, Ang II and analogues. Circ Res (Suppl II): 107–117

    Google Scholar 

  116. Peach MJ (1977) Renin-angiotensin system. Biochemistry and mechanism of acdon. Physiol Rev 57: 313–370

    CAS  PubMed  Google Scholar 

  117. Price DA, De’Oliveira JM, Fisher ND, Hollenberg NK (1997) Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 30 (2 PT 1): 240–6

    CAS  PubMed  Google Scholar 

  118. Quadri F, Badoer E, Stadler T, Unger Th (1991) Ang Il-induced noradrenaline release from anterior hypothalamus in conscious rats. A brain microdialysis study. Brain Res 563: 137–141

    Google Scholar 

  119. Raasch W, Häuser W, Dendorfer A, Schlecht T, Dominiak P (1996) Hypertrophieregression von Ventrikel und Aortenmedia an SHR: Beeinflussung des RAS auf verschiedenen Ebenen. Z Kardiol 85 (Suppl 2): 235–813

    Google Scholar 

  120. Reif M, White WB, Fagan TC, Oparil S, Flanagan TL, Edwards DT, Cushing DJ, Michelson EL (1998) Effects of Candesartan Cilexetil in Patients With Systemic Hypertension. Am J Cardiol 82: 961–965

    CAS  PubMed  Google Scholar 

  121. Ribstein J, Sissmann J, Picard A, Bouroudian M, Mimran A (1994) Effects of the angiotensin II antagonist SR 47436 (BMS-186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens 12: 131

    Google Scholar 

  122. Riddell JG (1997) Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexedl. J Hum Hypertens 11 (Suppl 2): S29–30

    CAS  PubMed  Google Scholar 

  123. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H (1994) Comparadve effects of chronic angiotensin-converting enzyme inhibition and Ang II type 1 receptor blockade on cardiac remodeling after myocardial infarcdon in the rat. Circulation 89: 2273–2282

    CAS  PubMed  Google Scholar 

  124. Schierok H, Pairet M, Hauel N et al. (1997) Effects of telmisartan, a new angiotensin AT, receptor antagonist, on renal excretory funcdon in conscious dogs [abstract]. 1st Internadonal Symposium on Angiotensin II Antagonism; Sept 28-Oct 1: London

    Google Scholar 

  125. SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265: 3255–3264

    Google Scholar 

  126. Shibouta Y, Inada Y, Ojima M et al. (1993) Pharmacological profile of a highly potent and long- acting angiotensin II receptor antagonist. 2-ethoxy-l-[[2’-(lH-tetrazol-5-yl)biphenyl-4-yl]methyl]-lH- benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (±)-l-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1 -[[2’-(1 H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1 H-benzimidazole-7-caraboxylate (TCV-116). J Pharmacol Exp Ther 266: 114–20

    CAS  PubMed  Google Scholar 

  127. Sica DA, Lo MW, Shaw WC et al. (1995) The pharmacokinedcs of losartan in renal insufficiency. J Hypertens 13 (Suppl 1): S49-S52

    CAS  Google Scholar 

  128. Siegl PKS (1993) Discovery of losartan, the first specific non-peptide Ang II receptor antagonist. J Hypertens 11 (Suppl3):S19-S22

    CAS  Google Scholar 

  129. Sissmann J, Bouroudian M, Armagnac C, Donazollo Y, Latreille M, Panis R (1994) Angiotensin II blockade in healthy volunteers: Tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS-186295). J Hypertens 12: S92

    Google Scholar 

  130. Smith DHG, Morgenstern P (1998) Once-Daily Telmisartan Compared With Enalapril in the Treatment of Hypertension. Advances in Therapy 15: 229–240

    CAS  Google Scholar 

  131. Smith MC, Barrows S, Meibohm A et al. (1995) The effects of Ang II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension. Am J Hypertens 8: 1177–1183

    CAS  PubMed  Google Scholar 

  132. Stangier J, Schmid J, Türck D et al. (1997) Pharmacokinetics of [14C]-radiolabelled telmisartan, a potent angiotensin II antagonist, in healthy male subjects (poster). 1st International Symposium on Angiotensin II Antagonism; Sept 28-Oct 1; London

    Google Scholar 

  133. Starke K, Taube HD, Borowski E (1977) Presynaptic receptor systems in catecholaminergic transmission. Biochem Pharmacol 26: 259–268

    CAS  PubMed  Google Scholar 

  134. Starke K (1971) Action of angiotensin on uptake, release and metabolism of [14C] noradrenaline by isolated rabbit hearts. Eur J Pharmacol 14: 112–113

    CAS  PubMed  Google Scholar 

  135. Staszewska-Barczak J, Vane JR (1967) The release of catecholamines from the adrenal medulla by peptides. Br J Pharmacol Chemother 30: 655–667

    CAS  PubMed Central  PubMed  Google Scholar 

  136. Stearns RA, Chakravarty PK, Chen R et al. (1995) Biotransformadon of losartan to its acdve carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3 A subfamily members. Drug Metab Dispos 23: 207–215

    CAS  PubMed  Google Scholar 

  137. Stearns RA, Miller RR, Doss GA et al. (1992) The metabolism of DuP753, a nonpepdde Ang II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab Dispos 20: 281–287

    CAS  PubMed  Google Scholar 

  138. Steckelings U, Obermüller N, Bottari SP, Quadri F, Veltmar A, Unger T (1992) Brain angiotensin: receptors, actions and possible role in hypertension. Pharmacol. Toxicol 70 (Suppl II): S23-S27

    CAS  PubMed  Google Scholar 

  139. Stier CT Jr, Sim G, Mahboubi K et al. (1991) Prevention of stroke and hypertensive renal disease by the Ang II receptor antagonist DuP 753 in salt-loaded stroke-prone SHR. In: MacGregor GA, Sever PS (eds) Current advances in ACE inhibition 2. Churchill Livingstone, Edinburgh London Melbourne New York Tokyo, pp 252–255

    Google Scholar 

  140. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T (1995) The angiotensin AT.-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95: 651–657

    CAS  PubMed Central  PubMed  Google Scholar 

  141. Sugimoto KI, Gotoh E, Takasaki I, Shionoiri H, Ishii M (1992) Effect of Ang II receptor antagonist on cardiac hypertrophy in Dahl salt sensitive rats. Hypertension 20: 419

    Google Scholar 

  142. Takeda K, Fujita H, Nakamura K et al. (1994) Effect of an angiotensin II receptor antagonists, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats. Blood Press 3 (Suppl 5): 94–8

    Google Scholar 

  143. Tang SS, Loscalzo J, Dzau VJ (1989) Tissue plasminogen activator activates renin angiotensin in vitro. J Vase Med Biol 1:67–74

    Google Scholar 

  144. Tenero D, Martin D, Chapelsky M, Ilson B, Boike S, Patterson S, Keogh J, Rodriguez S, Jorkasky D (1998) Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan. Pharmacotherapy 18: 42–50

    CAS  PubMed  Google Scholar 

  145. Tenero D, Martin D, Ilson B, Jushchyshyn J, Boike S, Lundberg D, Zariffa N, Boyle D, Jorkasky D (1998) Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bio- vailability and effect of food. Biopharm Drug Dispos 19: 351–6

    CAS  PubMed  Google Scholar 

  146. Tenero DM, Martin DE, Miller AK, Ilson B, Boike SC, Zariffa N, Jorkasky DK (1998) Effect of age and gender on the pharmacokinetics of eprosartan. Br J Clin Pharmacol 46: 267–70

    CAS  PubMed Central  PubMed  Google Scholar 

  147. The acute infarction ramipril efficacy (AIRE) study investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute mycardial infarction with clinical evidence of heart failure. Lancet 342: 821–828

    Google Scholar 

  148. The consensus trial study group (1987) Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316: 1429–1325

    Google Scholar 

  149. The studies of left ventricular dysfunction (SOLVD) investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685–691

    Google Scholar 

  150. Timmermans PBMWM, Smith RD (1996) Angiotensin-II-Rezeptoren: Physiologische und pharmakologische Bedeutung. In: Philipp Th, Schäfers RF (Hrsg) Angiotensin II - Antagonismus. Ein neuer Weg zur Hochdruckbehandlung. Springer, Berlin Heidelberg, S. 1–29

    Google Scholar 

  151. Timmermans PBMWM, Wong PC, Chiù AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD (1993) Ang II receptors and Ang II receptor antagonists. Parmacol Rev 45: 205–251

    CAS  Google Scholar 

  152. Tsunoda K, Abe K, Hagino T et al. (1993) Hypotensive effect of losartan, a nonpeptide Ang II receptor antagonist, in essential hypertension. Am J Hypertens 6: 28–32

    CAS  PubMed  Google Scholar 

  153. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Höhle S, Meffert S, Stoll M, Stroth U, Zhu Y-Z (1996) Angiotensin receptors. J Hypertens 14 (Suppl 5): S95-S103

    CAS  Google Scholar 

  154. Unger T, Gohlke P, Gruber MG (1990) Converting enzyme inhibitors. In: Ganten D, Mulrow PJ (eds) Pharmacology of Antihypertensive Therapeutics. Handbook of Experimental Pharmacology, Vol 93. Springer, Berlin Heidelberg New York Tokyo, pp 739–481

    Google Scholar 

  155. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A (1990) Ang Il-forming pathways in normal and failing human hearts. Circ Res 66: 883–890

    CAS  PubMed  Google Scholar 

  156. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A (1990) Identification of a highly specific chymase as the major angiotensin-II-forming enzyme in the human heart. J Biol Chem 265: 22348–22357

    CAS  PubMed  Google Scholar 

  157. Van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In’t Veld AJ, Schalekamp MADH (1995) Hemodynamic and biochemical effects of the AT, receptor antagonist irbesartan in hypertension. Hypertension 25: 22–29

    PubMed  Google Scholar 

  158. van Lier JJ, van Heiningen PNM, Sunzel M (1997) Absorption, metabolism and excretion of14C- candesartan and14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 11 (Suppl 2): S27–28

    PubMed  Google Scholar 

  159. van Meel JCA, Hauel N, Entzeroth M et al. (1993) Antihypertensive effects of the angiotensin receptor antagonist, BIBR 277, in conscious renal hypertensive and spontaneously hypertensive rats [abstract] Br J Pharmacol 108 (Suppl): 191P

    Google Scholar 

  160. van Meel JCA, Redemann N, Haigh RM (1996) Hypotensive effects of the angiotensin II antagonist telmisartan in conscious cronically-instrumented transgenic rats. Arzneimittel Forschung 46: 755–9

    PubMed  Google Scholar 

  161. Wada T, Inada Y, Shibouta Y, Ojima M, Kubo K, Kohara Y, Naka T, Nishikawa K (1992) Antihypertensive action of a nonpeptide Ang II (All) antagonist, TCV-116, in various hypertensive rats. J Hypertens 10 (Suppl 4): SI44

    Google Scholar 

  162. Wada T, Kanagawa R, Ishimura Y, Inada Y, Nishikawa K (1995) Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 13: 113–22

    CAS  PubMed  Google Scholar 

  163. Weinstock J, Keenan RM, Samanen J, Hempel J, Finkelstein JA, Franz RG, Gaitanopoulos DE, Girard GR, Gleason JG, Hill DT, Morgan TM, Peishoff CE, Aiyar N, Brooks DP, Fredrickson TA, Ohlstein EH, Ruffolo RR Jr, Stack EJ, Sulpizio AC, Weidley EF, Edwards RM (1991) l-(Carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem 34: 1514–1517

    Google Scholar 

  164. Wienen W, Entzeroth M, Diederen W et al. (1997) Pharmacology and antihypertensive effects of telmisartan, an AT,-selective angiotensin II receptor antagonist [poster] 1st International Symposium on Angiotensin II Antagonism. Sep 28-Oct 1; London

    Google Scholar 

  165. Wienen W, Hauel N, Van MJCA et al. (1993) Pharmacological characterization of the novel nonpepdde angiotensin II receptor antagonist. BIBR 277. Br J Pharmacol 110: 245–52

    CAS  PubMed Central  PubMed  Google Scholar 

  166. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G (1988) Primary prevendon with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259: 1976–1982

    CAS  PubMed  Google Scholar 

  167. Williams GH (1988) Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 319 (23): 1517–1525

    CAS  PubMed  Google Scholar 

  168. Winquist R, Panzenbeck M, Madwed J et al. (1994) The effects of BIBR 277, an angiotensin II type I (ATI) receptor antagonist in conscious monkeys [abstract]. FASEB J 8 (Pt 2): A882

    Google Scholar 

  169. Wintroub BU, Klickstein LB, Watt KW (1981) A human neutrophil dependent pathway for generadon of Ang IL J Clin Invest 68: 484–490

    CAS  Google Scholar 

  170. Wong PC, Hart SD, Chiù AT, Herblin WF, Carini DJ, Smith RD, Wexler RR, Timmermans PBMWM (1991) Pharmacology of DuP 532, a selective and noncompetitive AT, receptor antagonist. J Pharmacol Exp Ther 259: 861–870

    CAS  PubMed  Google Scholar 

  171. Wong PC, Hart SD, Duncia JV et al. (1991) Nonpeptide Ang II receptor antagonists. XIII. Studies with DuP 753 and EXP 3174 in dogs. Eur J Pharmacol 202: 323–330

    CAS  PubMed  Google Scholar 

  172. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM (1990) Nonpeptide Ang II receptor antagonists. XI. Pharmacology of EXP3174, an active metabolite of Dup 753 - an orally active antihypertensive agent. J Pharmacol Exp Ther 255: 211–217

    CAS  PubMed  Google Scholar 

  173. Wong PC, Price WA, Chiù AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM (1990) Nonpepdde Ang II receptor antagonists. IX. Andhypertensive acdvity in rats of DuP 753, an orally acdve antihypertensive agent. J Pharmacol Exp Ther 252: 726–732

    CAS  PubMed  Google Scholar 

  174. Wong PC, Price WA, Chiù AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM (1990) Nonpeptide Ang II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally acdve andhypertensive agent. J Pharmacol Exp Ther 252: 719–725

    CAS  PubMed  Google Scholar 

  175. Wong PC, Tam SW, Herblin WF et al. (1991) Further studies on the selecdvity of DuP 753, a nonpepdde Ang II receptor antagonist. Eur J Pharmacol 196: 201–203

    CAS  PubMed  Google Scholar 

  176. Wood JM, Schnell CR, Levens NR (1993) Kidney is an important target for the antihypertensive action of an Ang II receptor antagonist in spontaneously hypertensive rats. Hypertension 21: 1056–1061

    CAS  PubMed  Google Scholar 

  177. Wright JW, Krebs LT, Stobb JW, Harding JW (1995) The angiotensin IV system: funcdonal implications. Front Neuroendocrinol 16: 23–52

    CAS  PubMed  Google Scholar 

  178. Yoshiyama M, Kim S, Yamagishi H et al. (1994) Cardioprotecdve effect of the angiotensin II type I receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 128: 1–6

    CAS  PubMed  Google Scholar 

  179. Zierhut W, Studer R, Laurent D, Kästner S, Allegrini P, Whitebread S, Cumin F, Baum H, de Gasparo M, Drexler H (1996) Left ventricular wall stress and sarcoplasmic recdculum Ca2+-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibidon and AT,-receptor blockade. Cardiovasc Res 31: 758–768

    CAS  PubMed  Google Scholar 

  180. Zimmerman BG (1978) Acdons of angiotensin on adrenergic nerve endings. Fed Proc 37: 199–202

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für experimentelle und klinische Pharmakologie und Toxikologie, Med. Universität zu Lübeck, Ratzeburger Allee 160, D-23538, Lübeck, Deutschland

    Prof. Dr. med. P. Dominiak

Authors
  1. Prof. Dr. med. P. Dominiak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Dendorfer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für experimentelle und klinische Pharmakologie und Toxikologie, Med. Universität zu Lübeck, Ratzeburger Allee 160, D-23538, Lübeck, Deutschland

    Peter Dominiak

  2. Institut für Pharmakologie, Klinikum der Christian-Albrechts-Universität zu Kiel, Hospitalstraße 4, D-24105, Kiel, Deutschland

    Thomas Unger

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt

About this paper

Cite this paper

Dominiak, P., Dendorfer, A. (1999). Pharmakologie und klinische Pharmakologie der AT1-Rezeptorantagonisten. In: Dominiak, P., Unger, T. (eds) Angiotensin II AT1-Rezeptorantagonisten. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-93705-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93705-7_2

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-93706-4

  • Online ISBN: 978-3-642-93705-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation